Spyre Therapeutics, LLC
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 101
- Market Cap
- $1.4B
- Website
- http://www.spyre.com
Clinical Trials
6
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
A Study of SPY072 in Rheumatic Disease
- Conditions
- Rheumatoid ArthritisRheumatic Joint DiseasePsoriatic ArthritisAxial SpondyloarthritisRheumatic DiseasesAxSpAPsA (Psoriatic Arthritis)Rheumatologic Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-08-29
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Spyre Therapeutics, Inc.
- Target Recruit Count
- 285
- Registration Number
- NCT07148414
- Locations
- 🇺🇸
Site 108, Tujunga, California, United States
🇺🇸Site 101, Brookline, Massachusetts, United States
🇺🇸Site 103, Tomball, Texas, United States
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- Conditions
- Ulcerative ColitisInflammatory Bowel DiseasesColitisColitis, Ulcerative
- Interventions
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Spyre Therapeutics, Inc.
- Target Recruit Count
- 645
- Registration Number
- NCT07012395
- Locations
- 🇺🇸
Site 024, Colorado Springs, Colorado, United States
🇺🇦Site 913, Kyiv, Ukraine
🇺🇦Site 901, Lutsk, Ukraine
SPY003-207 in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- Drug: SPY003-207Other: Placebo
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Spyre Therapeutics, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT06873724
- Locations
- 🇨🇦
Spyre Site 1, Montréal, Quebec, Canada
A Study of SPY002-091 in Healthy Volunteers
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Spyre Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT06672718
- Locations
- 🇺🇸
Spyre Site 1, Cypress, California, United States
A Study of SPY002-072 in Healthy Volunteers
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Spyre Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT06622070
- Locations
- 🇺🇸
Spyre Site 2, Cypress, California, United States
🇨🇦Spyre Site 1, Montréal, Quebec, Canada
- Prev
- 1
- 2
- Next
News
Spyre Therapeutics Initiates Phase 1 Trial of Novel Long-Acting IL-23 Antibody for IBD Treatment
Spyre Therapeutics has dosed the first participant in a Phase 1 trial of SPY003, a half-life extended IL-23 antibody designed for potential quarterly or biannual dosing in inflammatory bowel disease patients.
Spyre Therapeutics' SPY001 Shows Promising Phase 1 Results for IBD Treatment
Spyre Therapeutics' SPY001 demonstrates a >90-day half-life in Phase 1 trials, suggesting potential for quarterly or bi-annual subcutaneous maintenance dosing in IBD.
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY001 in Healthy Volunteers
Spyre Therapeutics reports positive interim results from its Phase 1 trial of SPY001, a novel half-life extended anti-α4β7 antibody.
Spyre Therapeutics Advances IBD Pipeline with SPY001 and SPY002 Programs
Spyre Therapeutics is progressing its SPY001 program, an anti-a4ß7 monoclonal antibody, with interim Phase I data expected by year-end for IBD treatment.
Spyre Therapeutics Accelerates SPY003 (IL-23p19) Clinical Timelines Based on Preclinical Data
Spyre Therapeutics anticipates initiating first-in-human dosing of SPY003, a novel half-life extended anti-IL-23 monoclonal antibody, in Q1 2025, with interim data expected in the second half of 2025.